Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 27:11:1326426.
doi: 10.3389/fmed.2024.1326426. eCollection 2024.

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Siyu Zhu  1 , Xinyue Wang  2 , Hui Li  3   4 , Peiyan Zhao  3   4 , Jingjing Liu  5 , Liang Zhang  5 , Ying Cheng  3   4   5
Affiliations
Review

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Siyu Zhu et al. Front Med (Lausanne). .

Abstract

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma (HGNEC) accounting for 3% of primary lung cancer, and characterized by strong invasion, high heterogeneity, and extremely poor prognosis. At present, the diagnosis and treatment of LCNEC remains controversial and refer to therapeutic strategy of small cell lung cancer (SCLC), lacking precise therapy. Recently, the genetic analysis and clinical trials of LCNEC gradually emerged, providing more evidence for precise diagnosis and treatment. Here, we review the diagnosis, molecular characteristics, and treatment of LCNEC based on the existing research and frontier progress to provide a potential direction for future diagnosis and treatment of LCNEC.

Keywords: biomarkers; immunotherapy; molecular subtype; pulmonary large cell neuroendocrine carcinoma; therapeutic advances.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Chen Y, Zhang J, Huang C, Tian Z, Zhou X, Guo C, et al. Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: A retrospective single-institution analysis and literature review. Orphanet J Rare Dis. (2021) 16:82. 10.1186/s13023-021-01730-7 - DOI - PMC - PubMed
    1. Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, et al. Clinical features of large cell neuroendocrine carcinoma: A population-based overview. Eur Respir J. (2016) 47:615–24. 10.1183/13993003.00618-2015 - DOI - PubMed
    1. Fasano M, Della Corte C, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: From epidemiology to therapy. J Thorac Oncol. (2015) 10:1133–41. 10.1097/JTO.0000000000000589 - DOI - PMC - PubMed
    1. Noonan K, Derks J, Laskin J, Dingemans A-MC. Neuroendocrine tumors of the lung other than small cell lung cancer. IASLC Thorac Oncol. (2018) 2018:555–568.e6.
    1. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. (2022) 33:115–54. 10.1007/s12022-022-09708-2 - DOI - PubMed

LinkOut - more resources